Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

Novo Nordisk (NVO) announced on Friday that it has secured a legal victory against compounders selling unauthorized versions ...

Novo Nordisk has notched a major legal win against compounding pharmacies that make copies of its diabetes and obesity drug ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Novo Nordisk has awarded a 50 million kroner ($7.6M) grant to the University of Copenhagen to develop less processed ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

Ozempic, originally for type 2 diabetes, has surged in popularity in North America as a weight-loss solution, sparking a ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

WEIGHT loss injections have become the holy grail in the fight against obesity, helping people shift the pounds they’ve been ...

As meat alternative sales slide in the UK, a new crop of whole-food plant protein formats are on the rise – Oh So Wholesome's ...

Hospital trips tied to semaglutide—the active ingredient in Ozempic and Wegovy—are rare ... and bile duct disease rounded out the list, but were less commonly reported. The fact that most ...